D. Boral Capital Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at D. Boral Capital in a research report issued on Monday,Benzinga reports. They currently have a $25.00 target price on the stock.

Several other analysts also recently commented on HUMA. HC Wainwright began coverage on shares of Humacyte in a research report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target for the company. Wall Street Zen upgraded shares of Humacyte from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Benchmark decreased their target price on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Humacyte presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.71.

Humacyte Stock Performance

Shares of NASDAQ HUMA traded up $0.01 during mid-day trading on Monday, reaching $2.60. 1,667,405 shares of the company's stock were exchanged, compared to its average volume of 3,814,475. The firm has a market capitalization of $402.53 million, a price-to-earnings ratio of -1.94 and a beta of 2.00. The company's 50-day moving average is $1.79 and its 200-day moving average is $3.21. Humacyte has a 52-week low of $1.15 and a 52-week high of $9.79.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. As a group, equities analysts predict that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Kathleen Sebelius bought 50,000 shares of the company's stock in a transaction that occurred on Tuesday, April 8th. The shares were acquired at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the acquisition, the director now owns 91,207 shares in the company, valued at $120,393.24. This represents a 121.34% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Dale A. Sander purchased 20,000 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was bought at an average price of $1.53 per share, with a total value of $30,600.00. Following the acquisition, the chief financial officer now owns 40,600 shares in the company, valued at $62,118. This trade represents a 97.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 83,993 shares of company stock valued at $118,224. Company insiders own 5.10% of the company's stock.

Institutional Investors Weigh In On Humacyte

Hedge funds and other institutional investors have recently bought and sold shares of the business. Columbia Advisory Partners LLC acquired a new stake in shares of Humacyte during the first quarter worth approximately $27,000. Hamilton Lane Advisors LLC bought a new position in shares of Humacyte during the first quarter worth about $37,000. Letko Brosseau & Associates Inc. acquired a new position in shares of Humacyte in the 1st quarter worth approximately $42,000. Vontobel Holding Ltd. acquired a new position in shares of Humacyte in the 4th quarter valued at about $50,000. Finally, Petros Family Wealth LLC bought a new position in Humacyte in the fourth quarter worth about $50,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.